Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation

Annals of Hematology

Volumn 78, Issue 8, 1999, Pages 380-384

  Ferrara, Felicetto ^a,g   Melillo, L ^b   Montillo, M ^c   Leoni, F ^d   Pinto, A ^e   Mele, G ^a   Mirto, S ^f  

^a CARDARELLI HOSPITAL   (Italy)

^b Ospedale CSS   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^g NONE   (United States)

Author keywords

Acute myeloid leukemia; Autologous stem cell transplantation; Relapse

Indexed keywords

AMSACRINE; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; FEMALE; HOSPITALIZATION; HUMAN; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; LIVER DYSFUNCTION; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MYCOSIS; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RELAPSE; STEM CELL TRANSPLANTATION; STOMATITIS; SURVIVAL TIME; WHOLE BODY RADIATION;

EID: 0032825908     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050533     Document Type: Article

References (35)

1. Amadori S, Arcese W, Isacchi G, Meloni G. Petti MC, Monarca B, Testi AM, Mandelli F (1991) Miloxantrone, etoposide, and intermediate dose-cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 9:1210-1214
2. Bennett JM, Catovski D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:620-625
3. Buchner T, Hiddemann W, Wormann B, Zuhlsdorf M, Rottmann R, Innig G, Maschmeier G, Ludwig WD, Sauerland MC, Heinecke A (1997) Hematopoietic growth factors in acute myeloid leukemia: supporting and priming effects. Semin Oncol 24:124-131
4. Burnett AK, Goldstone AH, Stevens RMF, Hann IM, Gray RG, Wheatley K (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. Lancet 351:700-708
5. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarago M, Patrone F, Ghio R, Gobbi M (1996) High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 81:512-519
6. Clift RA, Buckner CD (1998) Marrow transplantation for acute myeloid leukemia. Cancer Invest 16:53-61
7. de la Rubia J, Sanz GF, Martin G, Sempere A, Picon I, Carral A, Larrea L, Martinez J, Soler MA, Bonanad S, Lopez F, Jarque I, Sanz MA (1996) Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. Bone Marrow Transplant 18:1167-1173
8. Estey E (1996) Treatment of refractory leukemia. Leukemia 10 [Suppl 2]: 39-43
9. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9:343-350
10. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Freireich E, Deisseroth A, Keating M (1994) Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671-678
11. Fleischack G, Hasan C, Graf A, Mann G, Bode U (1998) IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor prognosis AML of childhood or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol: 102:647-655
12. Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124
13. Goldman JM, Schmitz N, Niethammer D, Gratwhol A (1998) Allogeneic and autologous transplantation for haematological disease, solid tumors and immune disorders: current practice in Europe in 1998. Bone Marrow Transplant 21:1-7
14. Gorin NC (1998) Autologous stem cell transplantation in acute myelocytic leukemia. Blood 92:1073-1090
15. Gratwhol A, Hermans J, Tichelli A, Goldman JM, Gahrton G (1996) Indications for haemopoietic precursor cell transplants in Europe. Br J Haematol 92:35-43
16. Herzig RH, Lazarus HM, Wolff SN, Philips GL, Herzig GP (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3:992-997
17. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Buchner T (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myelogenous leukemia. Blood 69:744-749
18. Huhmann IM, Watzke HH, Geissler K, Gisslinger H, Jager U, Knobl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kahls P, Haas OA, Lechner K (1996) FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73:265-271
19. Imrie E, Dicke KA, Keating A (1996) Autologous bone marrow transplantation for acute myeloid leukemia. Stem Cells 14:69-78
20. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations, J Am Stat Assoc 53:457-481
21. Meloni G, Vignetti M, Avvisati G, Capria S, Micozzi A, Giona F, Mandelli F (1996) BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 18:693-699
22. Michelutti A, Michieli M, Damiani D (1997) Effect of fludarabine and arabinosylcytosine on multidrug-resistant cells. Haematologica 82:143-147
23. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F (1998) Fludarabine, cytarabine and G-CSF for the treatment of poor risk acute myeloid leukemia. Am J Hematol: 58:105-109
24. Nokes TJC, Johnson S, Harvey, Goldstone AH (1997) FLAG is a useful regimen for poor prognosis adult myeloid leukemias and myelodysplastic syndromes. Leuk Lymphoma 27:93-101
25. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SMB, Samartunga IM, Grace R, Gover A, Mufti GJ (1997) Fludarabine, cytarabine, idarubicin, G-CSF for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 99:939-944
26. Steinmetz HT, Staib A, Glasmacher A, Neufang I, Katay, Diehl V, Wickramanayake PD (1996) Phase II study of idarubicin, fludarabine, ARA-C, and G-CSF (IDA-FLAG) for treatment of refractory, relapsed or secondary acute myeloid leukemia. Br J Haematol [Suppl 2] 93:219a
27. Tafuri A, Andreef M (1990) Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826-834
28. Tafuri A, Lemoli RM, Chen R, Gulati SC, Clarkson BD, Andreef M (1994) Combinations of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle-specific and cycle-nonspecific drugs. Leukemia 8:749-757
29. Terpstra W, Lowemberg B (1997) Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 11:315-327
30. To Boekhorst PAW, Lowemberg B, Sonneveld P (1994) Hematopoietic growth factor stimulation and cytarabine toxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 8:1480-1486
31. Tomas F, Gomez-Garcia de Soria V, Lopez-Lorenzo JL, Arranz R, Figuera A, Camara R, Alegre A, Fernandez-Ramada JM (1996) Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. Bone Marrow Transplant 17:979-984
32. Tsai T, Goodman S, Saez R, Schiller G, Adkins D, Callander N, Wolff S, Freytes CO (1997) Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 20:859-863
33. Tutschka PJ, Copelan EA, Klein JP (1987) Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382-1388
34. Van der Lely, De Witte T, Wessels J, Raymakers R, Muus P, Preijers F (1994) In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance ARA-C sensitivity. Ann Hematol 68:225-232
35. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara B, Gobbi M, Tura S (1994) FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemias. Leukemia 8:1842-1846